Galecto, Inc. 8-K

What Happened

• Galecto, Inc. filed an 8-K announcing a formal name change to Damora Therapeutics, Inc. (Name Change Amendment filed March 6, 2026 and effective at 12:01 a.m. ET on March 10, 2026). The company issued a press release on March 9, 2026 announcing the name change and related symbol change.
• The company reported a preliminary, unaudited estimate of approximately $535 million in cash and cash equivalents as of February 28, 2026 (reported in the March 9, 2026 press release). The filing cautions this is management’s estimate and actual results may differ materially.

Key Details

• Name Change Amendment filed with Delaware Secretary of State on March 6, 2026; effective March 10, 2026.
• Common stock will continue to trade on The Nasdaq Capital Market, with ticker changing to “DMRA” at the open on March 10, 2026; CUSIP remains unchanged.
• The Board approved the name change under Section 242 of the Delaware General Corporation Law; stockholder approval was not required.
• Cash and cash equivalents: approximately $535 million as of Feb 28, 2026 (preliminary and unaudited estimate).

Why It Matters

• The filing documents a corporate rebranding (name and ticker change) that will affect how the company is identified by investors and in the market (new name Damora Therapeutics, new ticker DMRA starting March 10, 2026).
• The disclosed preliminary cash balance (~$535M) gives investors a current snapshot of liquidity and potential runway, but it is unaudited and subject to change, so final financial statements may differ.
• There is no change to shareholders’ voting rights, share validity, transferability, or the security’s CUSIP—only the company name and trading symbol are changing.